The role of cell-mediated cytotoxicity in the complex pathophysiology of graft-versus-host disease (GVHD) has remained poorly defined for several decades. We transplanted T cells from Fas-ligand (FasL)-defective and perforin-deficient mutant donor mice into lethally irradiated MHC-matched allogeneic recipient mice to characterize the role of cell-mediated cytotoxicity in GVHD. Although recipients of allogeneic FasL-defective donor T cells underwent severe GVHD-associated cachexia, they exhibited only minimal signs of hepatic and cutaneous GVHD pathology. Recipients ofperforin-deficient allogeneic donor T cells developed signs of acute GVHD, but the time of onset was significantly delayed. These findings demonstrate that Fas-mediated anti-recipient cytotoxicity may be critical for the development of hepatic and cutaneous GVHD, but is not required for GVHD-associated cachexia. In addition, perforinmediated anti-recipient cytotoxicity appears to play an important role in the kinetics of GVHD pathophysiology, but is not required for GVHD-associated tissue damage.
A llogeneic bone marrow transplantation (BMT) 1 has greatly expanded as a clinical treatment modality for several disorders of hematopoiesis and certain hematological malignancies (1) . Graft-versus-host disease (GVHD) remains a principal complication following allogeneic BMT occurring in up to 75% of recipients of unmanipulated HLAmatched marrow (2) . The immunopathophysiology of GVHD is complex, and is generally considered to involve two phases: an afferent (inductive) phase, and an efferent (effector) phase (3) . In the afferent phase, mature T cells present in the donor marrow inoculum recognize antigenic disparities expressed on recipient tissues resulting in alloactivation and proliferation of the allogeneic donor T cells. In the efferent phase, inflammatory reactions may develop in specific host target tissues such as skin, liver, and gastrointestinal tract that are characterized by mononuclear cell infiltration and histopathological damage (4) . Studies of experimental models ofaUogeneic BMT using T cell-depletion have demonstrated that mature T cells must be present in the donor marrow inoculum in order to induce GVHD, and several clinical studies have confirmed this finding (5, 6) . However, the precise role of T cell-mediated anti-recipient cy1Abbreviations used in this paper: BMT, bone marrow transplantation; DN, double negative; FasL, Fas ligand; GVHD, graft-versus-host disease. totoxicity in the pathophysiology of GVHD remains controversial (7) (8) (9) (10) (11) (12) (13) .
Recently, it has been demonstrated that perforin-dependent cytolysis and Fas-mediated apoptosis together constitute the major mechanisms of short-term T cell-mediated cytotoxicity (14) (15) (16) . T cells from mice which are homozygous for the gld (generalized lymphoproliferative disease) mutation are known to express a functionally defective Fas ligand (FasL) molecule which is not capable of transducing an apoptotic signal to Fas-bearing target cells (17) . The perforin-deficient (perforin 0/0) mutant mouse strain was developed by homologous recombination in a B6 embryonic stem cell line, and bred to homozygosity on a C57BL/6 background (18) . We have transplanted T cells from FasLdefective (gld) and pefforin-deficient (perforin 0/0) donor mice into lethally irradiated MHC-matched allogeneic recipient mice to determine the role of these cytotoxic pathways in acute GVHD.
The present studies demonstrate that Fas-mediated cytotoxicity plays an essential role in the pathophysiology of hepatic and cutaneous GVHD, but is not required for GVHinduced cachexia. Furthermore, the absence of perforinmediated cytotoxicity significantly delays the onset of GVHD, but does not prevent or diminish GVHD. These results suggest that certain local processes of GVHD such as tissue damage are separable from the systemic process of cachexia.
In addition, the Fas-mediated and perforin-dependent cytotoxic pathways appear to act during different stages in the complex pathophysiology of GVHD. The role of inflammatory cytokines is discussed.
.Materials and Methods
Mice. C57BL/6J (H-2b), B6.SmnC3H-gld (H-2b), LP/J (H-2b), and C3H.SW (H-2 b) mice were obtained from Jackson Laboratory (Bar Harbor, ME). Pefforin-deficient C57BL/6 mice (B6-pefforin 0/0) were obtained from D. K~igi and H. Hengartner (University of Zfirich, Switzerland) and B. Ledermann and K. Bfirki (Sandoz Pharma Ltd., Basel, Switzerland). B6-pefforin 0/0 mice were propagated at the University of Miami School of Medicine Specialized Animal Facility and were maintained in a pathogen-free colony until use.
Preparation of Cells. Bone marrow cells were aspirated from the femurs and tibias of donor mice. T cells were depleted from the bone marrow by incubation with anti-Thyl.2 mAb (30-H-12 culture supernatant) at 1:5 dilution and 4~ for 30 rain followed by Low-Tox M complement (Accurate Chemical Co., Westbury, NY) at 1:20 dilution and 37~ for 45 rain. Spleen and lymph node cells were harvested, pooled, and treated with anti-B220 mAb (14.8 culture supernatant) at 1:2.5 dilution and 4~ for 30 rain, followed by a secondary mouse anti-rat mAb (18.5 ascites) at 1:50 and 4~ for an additional 30 rain. The labeled cells were then treated with rabbit complement at 1:10 dilution and 37~ for 45 rain to remove B cells and enrich for T cells. This procedure routinely enriches the T cell population to levels of purity between 75-80% as determined by flow cytometric analysis.
Assay for GVHD. Recipient mice were exposed to 900 cGy TBI from a 6~ source at a dose rate of 50 cGy/min 24 h before the BMT. In murine models of GVHD, precise numbers of mature allogeneic donor T cells are routinely added together with bone marrow to induce lethal acute GVHD. The severity of GVHD correlates directly with the number of donor T cells transplanted (5) . The number of donor T cells was selected based upon the ability of the wild-type inoculum to induce characteristic signs of severe acute GVHD with an incidence of 100% in either donor/recipient strain combination. We transplanted 1 • 107 donor T cells in the B6-+LP combination, and 2 • 107 donor T ceils in the B6--)C3H.SW combination. To ensure reproducible results, the number of CD3 + T cells in the donor inoculum was precisely quantified by flow cytometry for each BMT. Precisely the same numbers of CD3 § T cells from wild-type, perforindeficient, or FasL-defective B6 donors were added to the T celldepleted bone marrow cells (5-10 • 106) from normal wild-type B6 donors and injected together into irradiated recipient mice intravenously via the lateral tail vein in a volume of 0.5 cc. Mice receiving transplants were distributed into groups containing 4-8 mice per group in each experiment. Recipients were maintained on acidified water (pH 3.0) containing antibiotics (100 mg/L neomycin sulfate, 10 mg/L polymyxin B) from day -3 to day 14 post-BMT. Recipient mice were monitored for clinical signs of GVHD including weight loss, skin lesions, alopecia, diarrhea, hunched posture, and mortality. Representative mice were killed at various times post-BMT to harvest tissues for histopathological analysis.
Histopathology. Skin and liver sections were harvested from recipients at various intervals after BMT. Tissues were placed in 10% buffered formalin phosphate (Fisher Scientific, Orlando, FL). The fixed tissues were paraffin embedded, sectioned, and stained with hematoxylin and eosin by the core service of the Department of Comparative Pathology at the University of Miami School of Medicine. Slides were coded and examined in a blinded fashion by NHA, and the tissue histology was graded.
Immunophenotyping. Pooled 
Results

Donor T Cells from B6-gld Mice Are Phenotypically and Functionally Normal.
Mice homozygous for the gld mutation develop lymphadenopathy characterized by progressive accumulation of functionally anergic B220+, CD4-, CD8-double negative (DN) T cells with significant numbers appearing after 6 wk of age (19, 20) . To ensure that we were not transplanting significant numbers of non-functional B220 + DN T cells, we used B6-gld mice which were 5-6 wk of age as donors. In addition, all detectable DN T cells and most B cells were removed by treating spleen and lymph node ceils with anti-B220 mAb (14.8) and complement that concurrently enriched the phenotypically normal T cells (Fig. 1 A) . Notably, the RA3-6B2 anti-B220 mAb used for immunophenotyping recognizes an epitope that is distinct from the epitope recognized by the 14.8 anti-B220 mAb, and binding of 14.8 does not block subsequent binding oftLA3-6B2 (21) . Syngeneic donor mice, wild-type allogeneic donor mice, and perforin-deficient donor mice were 6-8 wk of age. All donor T cell populations were prepared in the same fashion, and exhibited similar cellular subpopulations as determined by phenotypic analysis (data not shown).
To confirm that the enriched T ceil population purified from the gld donor mice was functionally competent, these cells were cultured in vitro in the presence of either soluble anti-CD3 mAb (2Cl1-145), concanavalin A, or irradiated allogeneic (C3H) spleen cells. The proliferative responses of the gld T cells to these polyclonal and alloantigen-specific stimuli was within normal limits compared to wild-type B6 T cells (Fig. 1 , B and C). plant experiment. All LP recipients ofsyngeneic T cells and marrow survived and regained normal body weight shortly after the transplant (Fig. 2) . In contrast, all LP recipients of wild-type allogeneic B6 T cells developed acute GVHD with severe weight loss and 100% mortality (Fig. 2) . Recipients of FasL-defective B6-gld T cells also exhibited severe weight loss and 100% mortality, indicating that they were undergoing a systemic graft-versus-host reaction (Fig. 2) . Mice of the C3H.SW (H-2 b) strain were transplanted to confirm the finding that FasL-defective T cells are capable of inducing a systemic GVH reaction in a second MHCmatched allogeneic donor/recipient strain combination. Again, all C3H.SW recipients of syngeneic T cells and marrow regained normal body weight rapidly after trans-
Marked Reduction of Rash but High Incidence of Cachexia and Mortality after
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plant. In contrast, all (100%) recipients of wild-type B6 or
B6-gld T cells exhibited severe cachexia (data not shown).
Recipient mice were monitored for clinical signs of acute GVHD following the transplant 9 Neither C3H,SW (Fig 3 A) nor LP recipients ofsyngeneic T cells ever developed any clinical signs of GVHD. The chnical appearance of mice that received wild-type allogeneic B6 T cells was characteristic of acute GVHD including marked weight loss, hunched posture, desquamative rash, and patchy alopecia ( Fig. 3 /3 ). In striking contrast, none of the mice receiving FasL-defective B6-gld T cells ever exhibited any signs of skin or coat involvement at any time after BMT although all developed severe weight loss (Fig. 3 C) . Results of clinical observations of groups of C3H.SW and LP mice from five ~s!~ 9 1o(7) 8o (Table 1) . ( Fig. 4 B) , alopecia, hunched posture, diarrhea, and desquamative skin rash with an incidence of 100% (Fig. 5 C) . H o wever, the average time of onset of these signs was delayed approximately twofold compared to the recipients of wildtype cells. The delay o f onset in the recipients of perforindeficient T cells was also apparent in the kinetics of mortality. There was a more than twofold increase in the mean survival time (65.3 vs 23.7 d) in the perforin-deficient recipient group compared to the wild-type recipient group (Fig. 4 A) . Results from seven independent experiments using either C 3 H . S W or LP strain mice as recipients confirmed that transplantation of perforin-deficient allogeneic Recipient mice were examined thrice weekly for clinical signs of acute GVHD including cachexia, alopecia, and desquamative rash. Results are expressed as the number of mice exhibiting signs compared to the total number of mice examined. Notably, the recipients of FasL-defective B6-gld T cells all developed cachexia, but none exhibited any signs of alopecia or rash throughout the study.
Marked Delay of G VHD and Mortality after Transplantation of Petforin-Deficient
T cells uniformly produces acute GVHD with a significant delay in time of onset (Table 1) .
Cutaneous G VHD Is Markedly Diminished in the Absence of FasL-mediated but Not
Petforin-mediated Anti-Recipient Cytotoxicity. Skin sections were harvested from representative mice at 28 d post-transplant to determine if the absence of perforin or Fas-mediated anti-recipient cytotoxicity would effect the incidence or severity of GVHD-associated pathology. Cutaneous sections from recipients ofsyngeneic T cells were unremarkable (Fig. 6 A) . Skin sections from C3H.SW recipients of 2 X 107 wild-type B6 T cells exhibited severe inflammation with mononuclear cell infiltrates, dermal fibrosis, loss of hair follicles, and epidermal hypertrophy consistent with cutaneous GVHD (Fig. 6 B) . In marked contrast, skin from C3H.SW recipients ofB6-gld T cells exhibited evidence of only minimal inflammation (Fig. 6 C) . On day 52, cutaneous sections from recipients of perforin-deficient B6 T cells exhibited alterations that were identical in character and severity to those observed in recipients of wild-type B6 T cells on day 28 (Fig. 6 D) . A second MHC-matched donor/recipient strain combination (B6-4LP) was employed to confirm this differential pattern of tissue damage after transplantation of cytotoxically defective T cells. These studies also demonstrated that cutaneous GVHD develops in the absence of perforinmediated anti-recipient cytotoxicity, but is markedly reduced in the absence of FasL-mediated anti-recipient cytotoxicity (data not shown). Mice receiving either wild-type B6 or B6-perforin 0/0 T cells developed acute GVHD with 100% mortality and severe weight loss. However, the time of onset for weight loss was delayed and the mean survival time was increased approximately twofold in the recipients ofperforin-deficient allogeneic T cells.
Hepatic GVHD Is Markedly
28 d post-transplant were unremarkable (Fig. 7 A) . Hepatic sections from. recipients of 2 • 107 wild-type B6 T cells exhibited a marked infiltrate of predominantly PMNs around bile ducts with associated partial inflammation and fibrosis that was evaluated as severe acute cholangitis consistent with hepatic GVHD (Fig. 7 B) . In marked contrast, liver sections from C3H.SW recipients of B6-gld T cells exhibited evidence of only minimal involvement (Fig. 7 C) . It is important to note that at no time after transplant of B6-gld T cells did the liver sections of these recipients exhibit significant hepatic pathology. On day 52, hepatic tissues from recipients of perforin-deficient B6 T cells exhibited severe cholangiohepatitis (Fig. 7 D) . A second MHC-matched donor/recipient strain combination (B6---~LP) was employed to confirm this differential pattern of tissue damage These studies also demonstrated that hepatic G V H D develops in the absence of perforin-mediated anti-recipient cytotoxicity, but is markedly reduced in the absence of FasLmediated anti-recipient cytotoxicity (data not shown).
There is evidence in the literature that epithelial damage in gastrointestinal G V H D lesions is characterized by apoptosis and D N A fragmentation (22) . Therefore, we were interested to examine the role of Fas-mediated cytotoxicity in gastrointestinal GVHD. Clinical evidence of diarrhea was observed in some but not all recipients of wild-type, FasL-defective, and perforin-deficient allogeneic T cells. In addition, histopathological evidence of acute colitis and enteritis was occasionally observed in recipients of wild-type, FasL-defective, and perforin-deficient allogeneic T cells (data not shown). Therefore, defects in individual cytotoxic pathways did not consistently abrogate either clinical or histopathological sequelae associated with gastrointestinal GVHD.
Recipients of FasL-defective Allogen& T Cells Do Not Exhibit
Lymphoid Atrophy. Recipient splenic lymphocytes were harvested and analyzed by flow cytometry 28 d after transplant to examine the status of the lymphoid compartment. Table 2 shows the numbers of spleen cells recovered from these recipients. Mice receiving wild-type or perforin-deficient allogeneic T cells exhibited profoundly decreased spleen cell recoveries that are typically observed in murine models of acute G V H D (Table 2) . Notably, recipients of FasL-defective T cells exhibited a somewhat increased spleen cell recovery, but did not exhibit evidence of uncontrolled lymphoproliferative disease (Table 2 ). These findings have been observed in seven independent transplantation experiments.
Mice that received syngeneic (C3H.SW) T cells exhibited normal percentages of B220+ cells (54.0%) and C D 3 + ceils (23.1%) in the spleen (Fig. 8 E) . Light scatter profiles of spleen ceils from recipients of wild-type allogeneic T cells (Fig. 8 /3 ) showed a markedly reduced lymphoid cell population (Region 1), which was comprised of 71.3% C D 3 + T cells (Fig. 8 F) . This pattern is consistent with acute G V H D (23) . A very similar pattern of lymphoid hypoplasia and spleen cell phenotype was observed in spleens from recipients of perforin-deficient allogeneic T cells in which 81.2% of the gated cells were C D 3 + (Fig. 8, C and G) . In contrast, the degree of lymphoid hypoplasia was less severe in the recipients of FasL-defective T cells as determined by light scatter (Fig. 8 D) . In addition, the percentage orB220+ cells was increased to 28.0% in the recipients of FasL-defective T cells (Fig. 8 H) compared to 2.6% in the recipients of wildtype T cells. However, as expected the percentage of CD3 + T cells (54.2%) was elevated in the recipients of FasL-defective T cells consistent with a GVHD-associated expansion of alloreactive donor T cells.
Discussion
The role of cell-mediated anti-recipient cytotoxicity in the pathophysiology of G V H D has remained poorly defined and controversial for several decades. To begin resolving the long standing controversy regarding the role of anti-recipient specific cell-mediated cytotoxicity in GVHD, we have compared the ability of FasL-defective, perforin-deficient, and wild-type allogeneic T ceils to induce severe acute G V H D across n o n -M H C antigenic barriers in mice. The results of the present study demonstrate that Fas-mediated cytotoxicity plays an important role in the pathophysiology of hepatic and cutaneous G V H D after B M T between M H C -m a t c h e d allogeneic mice. However, Fas-mediated anti-recipient cytotoxicity is not required for the induction of GVHD-associated cachexia, Furthermore, transplantation of perforin- deficient T cells results in a marked delay in onset of GVHD and mortality compared to GVHD induced by wild-type aUogeneic T cells. However, severe acute GVHD ultimately does develop with all of the classical hallmarks of GVHD including hunched posture, weight loss, alopecia, rash, cholangitis, and dermatitis.
The morphological and ultrastructural features of lesions in hepatic, cutaneous, and gastrointestinal GVHD have previously been reported to involve some degree of individual cell necrosis, pyknotic nuclei, and apoptotic bodies consistent with a role for apoptosis in GVHD-associated tissue damage (24) (25) (26) . In addition, both liver and skin tissues are known to express Fas (27) , and mice injected with the antiFas monoclonal antibody Jo2 rapidly develop a fulminant lethal hepatitis (28) . Furthermore, it has been reported recently that expression of Fas is upregulated in epidermal tissues undergoing certain inflammatory conditions (29) . Thus, skin and liver could be potential targets for FasL-bearing cytotoxic donor T cells after allogeneic BMT. Consistent with our findings that GVHD-associated cholangitis and dermatitis is markedly reduced in the absence of Fas-mediated cytotoxicity, we propose that this pathway may be an essential step in the multi-step process that ultimately leads to GVHD-associated inflammation and tissue damage in recipient liver and skin tissues. However, the findings in the present study do not suggest that Fas-mediated cytotoxicity is the only effector mechanism contributing to hepatic and cutaneous GVHD.
While hepatic and cutaneous pathology was markedly reduced in recipients o f FasL-defective donor T cells, these recipients exhibited severe cachexia and lost on average 35% of their initial body weight and virtually all body fat by day 28 post-BMT. T u m o r necrosis factor (TNF-~x, cachectin) produced by alloactivated FasL-defective donor T cells could account for the profound wasting and mortality observed in the recipients o f the B6-gld T cells. TNF-~x has been identified as a principal mediator of cachexia in rodents (30) . In addition, serum levels of T N F have been shown to be increased in patients undergoing G V H D after allogeneic BMT (31) . Notably, Piguet et al. demonstrated that administration of anti-TNF-c~ anti-sera markedly reduces recipient weight loss and mortality in a mouse model o f G V H D (32) .
Despite significant work, it has remained difficult to reconcile the classical concept of MHC-restricted T cellmediated cytotoxicity with the observation that highly pu- GVHD pathology is that cytotoxic T cells (CTL) of either phenotype may effect allogeneic cytotoxicity via FasL. Notably, it has recently been reported that CD4+ CTL may kill primarily through the Fas pathway (34) .
It is important to note that we have observed no evi- The finding that recipients of perforin-deficient allogeneic T cells exhibited clinical and histopathological signs of GVHD equivalent in severity to the signs observed in recipients of wild-type allogeneic T cells conclusively demonstrates that perforin-mediated cytotoxicity is not a critical effector function during the effector phase of GVHD. Lymphocyte subpopulation numbers are calculated based on percentages derived from phenotypic analysis (see Fig. 8 ). Significantly increased numbers of phenotypically normal B cells (B220+CD3-) are recovered from recipients of FasL-defective allogeneic T cells compared to recipients of wild-type and perforin-deficient allogeneic T cells. Notably, mice receiving B6-gld T cells did not exhibit an abnormally expanded population of
B220+ DN T cells (B220+CD3+).
We conclude that perforin-mediated donor anti-host cytotoxic function is not an absolute requirement for the development of GVHD across minor histocompatibility barriers. While perforin-deficient allogeneic T cells are clearly capable of inducing severe acute GVHD, the recipients of these cells have consistently exhibited a significant delay in the time of onset of clinical signs associated with GVHD and a prolonged MST. This finding suggests that perforinmediated cytotoxicity may be playing an important role in the early post-transplant period during the afferent phase of GVHD that could lead to a shift in kinetics without diminishing the ultimate severity of tissue damage and clinical signs of GVHD. Notably, preliminary results in our laboratory suggest that transplantation of perforin-deficient T cells at a dose twofold higher than the wild-type T cells resuits in onset of GVHD with no delay compared to the recipients of the lower dose of normal ceils. In addition, we have found that when very low numbers of bone marrowderived perforin-deficient T cells are transplanted the onset of GVHD is delayed indefinitely (37) .
One potential explanation for the delayed onset of GVHD in recipients of pefforin-deficient T cells is that perforinmediated cytotoxicity may accelerate and amplify the donor anti-host immune reaction. This may occur as a result of the release of inflammatory cytoplasmic contents following cytolysis of host target cells. When perforin-mediated anti-host cytolytic activity is absent, the resulting alloagressive reaction might be slowed. Alternatively, perforinmediated donor anti-host cytotoxic activity may be critical for overcoming residual host resistance in the recipient. Thus, in the absence of perforin-mediated anti-host cytotoxicity, host resistance would remain stronger and persist longer in the recipient diminishing the relative alloaggressive capacity of the perforin-deficient inoculum.
One advantage of employing genetically modified or naturally occurring mutant mouse strains as a source of donor T cells is that only one cytotoxic pathway has been selectively abrogated leaving the other cytotoxic effector functions intact. Cytotoxic T cells and NK cells from perforin-deficient mice exhibit profoundly diminished in vitro cytolytic function, but retain the ability to effect Fas-mediated and TNFmediated kilhng (15) . Alternatively, the Fas-ligand molecule expressed by T cells from gld mice is non-functional, but perforin-dependent cytolytic function remains intact. Therefore, these experiments were able to directly examine the role of each cytotoxic pathway by its absence, while simultaneously confirming the function of the other by its presence. Accordingly, consistent with the marked diminishment of hepatic and cutaneous GVHD following transplantation of FasL-defective T cells, GVHD developed in these tissues following transplantation of perforin-deficient T cells because Fas-mediated cytotoxic function remains intact. Another advantage of employing T cells with molecular defects in cytolytic function is that the defect is present in every donor cell of all phenotypes regardless of how these populations may interact and contribute to the development of GVHD.
Previous studies designed to examine effector functions in GVHD have employed transplantation of cell populations that have been negatively selected on the basis of immunophenotype (e.g., CD8+, CD4+, NKI.I+ cells). In studies involving negative selection, all potential cytotoxic and cytokine effector functions of the depleted cell population are removed along with the negatively selected population. In contrast, the present study is designed so that the potential to produce multiple inflammatory cytokines such as IL-1, IFN-y, and TNF-o~ by the cytotoxically defective T cells remains intact. These cytokines are known to be produced by alloactivated donor T cells during GVHD, and appear to contribute significantly to both inductive and effector phases of GVHD (38) .
The results of the present studies represent the first characterization of the role of Fas and perforin-mediated antirecipient cytotoxic function in the pathogenesis of GVHD after allogeneic bone marrow transplantation across non-MHC genetic disparities. These results demonstrate that Fasmediated cytotoxicity is required for the development of hepatic and cutaneous GVHD, but is not required for GVHD-associated cachexia. This finding has shown that local and systemic effects of GVHD are separable. Furthermore, the results also demonstrate that absence of perforinmediated anti-recipient cytotoxicity does not prevent or diminish GVHD, but significantly delays the time of onset. We interpret this finding to indicate that while perforinmediated cytotoxic function is not required for the effector phase of GVHD, this cytotoxic pathway appears to play a significant role during the inductive phase of GVHD. We conclude that the two major pathways of cell-mediated cytotoxicity play distinct roles in the complex pathophysiology of GVHD, and that these roles appear to be expressed during different stages of GVHD pathogenesis.
